China to strengthen anti-monopoly efforts in pharma industry By Reuters
© Reuters. Shelves displaying medicines are seen at a pharmacy in Shanghai, China, November 27, 2015. REUTERS/Aly Song/File Photo
BEIJING (Reuters) – China will toughen law enforcement to curb monopoly practices and unfair competition in the pharmaceutical industry as the government seeks to foster a good business environment, the industry ministry said on Sunday.
The action follows November’s regulatory guidelines to stamp out monopolies in active pharmaceutical ingredients (API). China leads the world in making and exporting these products.
In a statement, the ministry of industry and information technology said it would “strengthen law enforcement against unfair competition, and resolutely investigate unfair competitive acts, such as commercial bribery”.
It will also stiffen enforcement of anti-monopoly laws in the areas of drug shortages and APIs, prepare and adopt antitrust guidelines in the API market and investigate monopolistic pacts, it added.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.